CONSOLIDATED SCHEDULE OF INVESTMENTS £ in Thousands, $ in Thousands |
Dec. 31, 2022
USD ($)
shares
|
Dec. 31, 2022
GBP (£)
shares
|
Dec. 31, 2021
USD ($)
shares
|
Dec. 31, 2021
GBP (£)
shares
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
|
7.50%
|
|
7.50%
|
|
|
|
|
|
Investment cost |
|
$ 3,005,696
|
|
|
|
$ 2,390,984
|
|
|
|
Total investments at fair value |
|
2,963,955
|
|
|
|
2,434,522
|
|
|
|
Investment Funds & Vehicles [Member] |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[1] |
|
|
|
|
2,032
|
|
|
|
Total investments at fair value |
|
3,893
|
|
|
|
1,814
|
|
|
|
Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Total investments at fair value |
|
2,741,388
|
|
|
|
2,156,709
|
|
|
|
Unsecured |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Total investments at fair value |
|
54,056
|
|
|
|
52,890
|
|
|
|
Debt Investments |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
2,818,060
|
[2] |
|
|
2,219,586
|
[1] |
|
|
Total investments at fair value |
|
2,795,444
|
|
|
|
2,209,599
|
|
|
|
Equity |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
153,173
|
[2] |
|
|
142,219
|
|
|
|
Total investments at fair value |
|
133,972
|
|
|
|
184,710
|
|
|
|
Equity | Preferred Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Total investments at fair value |
|
41,488
|
|
|
|
69,439
|
|
|
|
Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Total investments at fair value |
|
92,484
|
|
|
|
115,271
|
|
|
|
Warrant Investment |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
30,964
|
[2] |
|
|
27,147
|
[1] |
|
|
Total investments at fair value |
|
30,646
|
|
|
|
38,399
|
|
|
|
Investments in Securities |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
3,002,197
|
[2] |
|
|
2,388,952
|
[1] |
|
|
Total investments at fair value |
|
2,960,062
|
|
|
|
2,432,708
|
|
|
|
Investment |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
3,005,696
|
[2] |
|
|
2,390,984
|
[1] |
|
|
Total investments at fair value |
|
2,963,955
|
|
|
|
2,434,522
|
|
|
|
Forbion Growth Opportunities Fund I C V | Investment Funds & Vehicles [Member] |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[3],[4],[5] |
|
|
|
|
2,032
|
|
|
|
Total investments at fair value |
[3],[4],[5] |
|
|
|
|
$ 1,814
|
|
|
|
Acquisition Date |
[6] |
|
|
|
|
Nov. 16, 2020
|
|
Nov. 16, 2020
|
|
Black Crow AI, Inc. affiliates |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Principal Amount |
|
|
|
|
|
$ 3,000
|
|
|
|
Medrobotics Corporation [Member] | Warrant Investment | Preferred Series E |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Acquisition Date |
[6] |
|
|
|
|
Mar. 13, 2013
|
|
Mar. 13, 2013
|
|
Biotechnology Tools |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Total investments at fair value |
|
32,825
|
|
|
|
$ 0
|
|
|
|
Biotechnology Tools | Debt Investments |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
32,339
|
|
|
|
|
|
|
|
Total investments at fair value |
|
32,339
|
|
|
|
|
|
|
|
Biotechnology Tools | Warrant Investment |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
485
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 486
|
|
|
|
|
|
|
|
Biotechnology Tools | Alamar Biosciences, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-06
|
|
2026-06
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
6.50%
|
|
6.50%
|
|
|
|
|
|
Investment Interest Rate Paid in Kind |
[7] |
1.00%
|
|
1.00%
|
|
|
|
|
|
Principal Amount |
[8] |
$ 5,000
|
|
|
|
|
|
|
|
Investment cost |
[2],[8] |
4,951
|
|
|
|
|
|
|
|
Total investments at fair value |
[8] |
$ 4,951
|
|
|
|
|
|
|
|
Biotechnology Tools | Alamar Biosciences, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
5.95%
|
|
5.95%
|
|
|
|
|
|
Biotechnology Tools | Alamar Biosciences, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
3.00%
|
|
3.00%
|
|
|
|
|
|
Biotechnology Tools | Alamar Biosciences, Inc. | Warrant Investment | Preferred Series B |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 24
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 23
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Jun. 21, 2022
|
|
Jun. 21, 2022
|
|
|
|
|
|
Shares | shares |
|
15,399
|
|
15,399
|
|
|
|
|
|
Biotechnology Tools | PathAI, Inc | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2027-01
|
|
2027-01
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
9.15%
|
|
9.15%
|
|
|
|
|
|
Principal Amount |
[8] |
$ 28,000
|
|
|
|
|
|
|
|
Investment cost |
[2],[8] |
27,388
|
|
|
|
|
|
|
|
Total investments at fair value |
[8] |
$ 27,388
|
|
|
|
|
|
|
|
Biotechnology Tools | PathAI, Inc | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
11.21%
|
|
11.21%
|
|
|
|
|
|
Biotechnology Tools | PathAI, Inc | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
2.15%
|
|
2.15%
|
|
|
|
|
|
Biotechnology Tools | PathAI, Inc | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 461
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 463
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Dec. 23, 2022
|
|
Dec. 23, 2022
|
|
|
|
|
|
Shares | shares |
|
53,418
|
|
53,418
|
|
|
|
|
|
Communications & Networking |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 101,833
|
|
|
|
105,490
|
|
|
|
Communications & Networking | Debt Investments |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
99,167
|
[2] |
|
|
97,088
|
[1] |
|
|
Total investments at fair value |
|
101,734
|
|
|
|
99,230
|
|
|
|
Communications & Networking | Equity |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[1] |
|
|
|
|
1,230
|
|
|
|
Total investments at fair value |
|
|
|
|
|
6,260
|
|
|
|
Communications & Networking | Warrant Investment |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
541
|
[2] |
|
|
418
|
|
|
|
Total investments at fair value |
|
$ 99
|
|
|
|
$ 0
|
|
|
|
Communications & Networking | Aryaka Networks, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-07
|
|
2026-07
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
6.75%
|
|
6.75%
|
|
|
|
|
|
Investment Interest Rate Paid in Kind |
[7] |
1.05%
|
|
1.05%
|
|
|
|
|
|
Principal Amount |
[8],[10],[11] |
$ 5,023
|
|
|
|
|
|
|
|
Investment cost |
[2],[8],[10],[11] |
4,969
|
|
|
|
|
|
|
|
Total investments at fair value |
[8],[10],[11] |
$ 5,053
|
|
|
|
|
|
|
|
Communications & Networking | Aryaka Networks, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
3.55%
|
|
3.55%
|
|
|
|
|
|
Communications & Networking | Aryaka Networks, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
3.25%
|
|
3.25%
|
|
|
|
|
|
Communications & Networking | Aryaka Networks, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 123
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 99
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Jun. 28, 2022
|
|
Jun. 28, 2022
|
|
|
|
|
|
Shares | shares |
|
229,611
|
|
229,611
|
|
|
|
|
|
Communications & Networking | Cytracom Holdings LLC | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2025-02
|
|
2025-02
|
|
2025-02
|
|
2025-02
|
|
Investment Interest Rate Floor |
|
10.31%
|
[7] |
10.31%
|
[7] |
10.31%
|
[12] |
10.31%
|
[12] |
Principal Amount |
|
$ 8,910
|
[8],[13],[14] |
|
|
$ 9,000
|
[3],[15],[16] |
|
|
Investment cost |
|
8,768
|
[2],[8],[13],[14] |
|
|
8,802
|
[1],[3],[15],[16] |
|
|
Total investments at fair value |
|
$ 8,748
|
[8],[13],[14] |
|
|
$ 8,725
|
[3],[15],[16] |
|
|
Communications & Networking | Cytracom Holdings LLC | Senior Secured Debt | LIBOR |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
|
9.31%
|
[7] |
9.31%
|
[7] |
9.31%
|
[12] |
9.31%
|
[12] |
Communications & Networking | Spring Mobile Solutions, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 418
|
[2] |
|
|
$ 418
|
|
|
|
Total investments at fair value |
|
|
|
|
|
$ 0
|
|
|
|
Acquisition Date |
|
Apr. 19, 2013
|
[9] |
Apr. 19, 2013
|
[9] |
Apr. 19, 2013
|
[6] |
Apr. 19, 2013
|
[6] |
Shares | shares |
|
2,834,375
|
|
2,834,375
|
|
2,834,375
|
|
2,834,375
|
|
Communications & Networking | Rocket Lab Global Services, LLC | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2024-06
|
|
2024-06
|
|
2024-06
|
|
2024-06
|
|
Investment Interest Rate Floor |
|
8.15%
|
[7] |
8.15%
|
[7] |
8.15%
|
[12] |
8.15%
|
[12] |
Investment Interest Rate Paid in Kind |
|
1.25%
|
[7] |
1.25%
|
[7] |
1.25%
|
[12] |
1.25%
|
[12] |
Principal Amount |
|
$ 84,581
|
[11],[13],[17],[18],[19] |
|
|
$ 88,542
|
[20],[21] |
|
|
Investment cost |
|
85,430
|
[2],[11],[13],[17],[18],[19] |
|
|
88,286
|
[1],[20],[21] |
|
|
Total investments at fair value |
|
$ 87,933
|
[11],[13],[17],[18],[19] |
|
|
$ 90,505
|
[20],[21] |
|
|
Communications & Networking | Rocket Lab Global Services, LLC | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
|
3.25%
|
[7] |
3.25%
|
[7] |
3.25%
|
[12] |
3.25%
|
[12] |
Communications & Networking | Rocket Lab Global Services, LLC | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
|
4.90%
|
[7] |
4.90%
|
[7] |
4.90%
|
[12] |
4.90%
|
[12] |
Communications & Networking | Peerless Network Holdings, Inc. | Equity |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[1] |
|
|
|
|
$ 1,230
|
|
|
|
Total investments at fair value |
|
|
|
|
|
$ 6,260
|
|
|
|
Shares | shares |
|
|
|
|
|
1,138,328
|
|
1,138,328
|
|
Communications & Networking | Peerless Network Holdings, Inc. | Equity | Preferred Series A |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[1] |
|
|
|
|
$ 1,230
|
|
|
|
Total investments at fair value |
|
|
|
|
|
$ 6,242
|
|
|
|
Acquisition Date |
[6] |
|
|
|
|
Apr. 11, 2008
|
|
Apr. 11, 2008
|
|
Shares | shares |
|
|
|
|
|
1,135,000
|
|
1,135,000
|
|
Communications & Networking | Peerless Network Holdings, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[1] |
|
|
|
|
$ 0
|
|
|
|
Total investments at fair value |
|
|
|
|
|
$ 18
|
|
|
|
Acquisition Date |
[6] |
|
|
|
|
Oct. 21, 2020
|
|
Oct. 21, 2020
|
|
Shares | shares |
|
|
|
|
|
3,328
|
|
3,328
|
|
Consumer & Business Products |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 2,821
|
|
|
|
$ 28,099
|
|
|
|
Consumer & Business Products | Debt Investments |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[1] |
|
|
|
|
23,162
|
|
|
|
Total investments at fair value |
|
|
|
|
|
23,298
|
|
|
|
Consumer & Business Products | Equity |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
663
|
[2] |
|
|
128
|
[1] |
|
|
Total investments at fair value |
|
498
|
|
|
|
447
|
|
|
|
Consumer & Business Products | Warrant Investment |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
1,712
|
[2] |
|
|
2,145
|
[1] |
|
|
Total investments at fair value |
|
2,323
|
|
|
|
4,354
|
|
|
|
Consumer & Business Products | TechStyle, Inc. | Warrant Investment | Preferred Series B |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
1,101
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 745
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Jul. 16, 2013
|
|
Jul. 16, 2013
|
|
|
|
|
|
Shares | shares |
|
206,185
|
|
206,185
|
|
|
|
|
|
Consumer & Business Products | Whoop, Inc. | Warrant Investment | Preferred Series C |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 18
|
[2] |
|
|
18
|
[1] |
|
|
Total investments at fair value |
|
$ 475
|
|
|
|
$ 1,847
|
|
|
|
Acquisition Date |
|
Jun. 27, 2018
|
[9] |
Jun. 27, 2018
|
[9] |
Jun. 27, 2018
|
[6] |
Jun. 27, 2018
|
[6] |
Shares | shares |
|
686,270
|
|
686,270
|
|
686,270
|
|
686,270
|
|
Consumer & Business Products | The Neat Company | Common Stock | Preferred Series C |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Total investments at fair value |
|
|
|
|
|
$ 0
|
|
|
|
Consumer & Business Products | The Neat Company | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 365
|
[2] |
|
|
$ 365
|
[1] |
|
|
Total investments at fair value |
|
|
|
|
|
|
|
|
|
Acquisition Date |
|
Aug. 13, 2014
|
[9] |
Aug. 13, 2014
|
[9] |
Aug. 13, 2014
|
[6] |
Aug. 13, 2014
|
[6] |
Shares | shares |
|
54,054
|
|
54,054
|
|
54,054
|
|
54,054
|
|
Consumer & Business Products | Grove Collaborative, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
|
|
|
|
2025-04
|
|
2025-04
|
|
Investment Interest Rate Floor |
[12] |
|
|
|
|
8.75%
|
|
8.75%
|
|
Principal Amount |
[22] |
|
|
|
|
$ 23,520
|
|
|
|
Investment cost |
[1],[22] |
|
|
|
|
23,162
|
|
|
|
Total investments at fair value |
[22] |
|
|
|
|
$ 23,298
|
|
|
|
Consumer & Business Products | Grove Collaborative, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[12] |
|
|
|
|
6.75%
|
|
6.75%
|
|
Consumer & Business Products | Grove Collaborative, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[12] |
|
|
|
|
5.50%
|
|
5.50%
|
|
Consumer & Business Products | Grove Collaborative, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[9] |
$ 433
|
|
|
|
|
|
|
|
Total investments at fair value |
[9] |
$ 24
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Apr. 30, 2021
|
|
Apr. 30, 2021
|
|
|
|
|
|
Shares | shares |
[9] |
61,300
|
|
61,300
|
|
|
|
|
|
Consumer & Business Products | Grove Collaborative, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[1] |
|
|
|
|
$ 433
|
|
|
|
Total investments at fair value |
|
|
|
|
|
$ 326
|
|
|
|
Acquisition Date |
[6] |
|
|
|
|
Apr. 30, 2021
|
|
Apr. 30, 2021
|
|
Shares | shares |
|
|
|
|
|
83,625
|
|
83,625
|
|
Consumer & Business Products | Penumbra Brands, LLC (p.k.a. Gadget Guard) | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[1] |
|
|
|
|
$ 228
|
|
|
|
Total investments at fair value |
|
|
|
|
|
$ 0
|
|
|
|
Acquisition Date |
[6] |
|
|
|
|
Jun. 03, 2014
|
|
Jun. 03, 2014
|
|
Shares | shares |
|
|
|
|
|
1,662,441
|
|
1,662,441
|
|
Consumer & Business Products | TFG Holding, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 89
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 116
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Apr. 30, 2010
|
|
Apr. 30, 2010
|
|
|
|
|
|
Shares | shares |
|
42,989
|
|
42,989
|
|
|
|
|
|
Consumer & Business Products | TFG Holding, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 0
|
|
|
|
|
|
|
|
Total investments at fair value |
|
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Jun. 27, 2014
|
|
Jun. 27, 2014
|
|
|
|
|
|
Shares | shares |
|
206,185
|
|
206,185
|
|
|
|
|
|
Consumer & Business Products | Savage X Holding, LLC | Equity | Class A Units |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 13
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 226
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Apr. 30, 2010
|
|
Apr. 30, 2010
|
|
|
|
|
|
Shares | shares |
|
42,137
|
|
42,137
|
|
|
|
|
|
Consumer & Business Products | Savage X Holding, LLC | Warrant Investment | Class A Units |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 0
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 1,103
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Jun. 27, 2014
|
|
Jun. 27, 2014
|
|
|
|
|
|
Shares | shares |
|
206,185
|
|
206,185
|
|
|
|
|
|
Consumer & Business Products | TechStyle, Inc. (p.k.a. Just Fabulous, Inc.) | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 128
|
[2] |
|
|
$ 128
|
[1] |
|
|
Total investments at fair value |
|
$ 132
|
|
|
|
$ 447
|
|
|
|
Acquisition Date |
|
Apr. 30, 2010
|
[9] |
Apr. 30, 2010
|
[9] |
Apr. 30, 2010
|
[6] |
Apr. 30, 2010
|
[6] |
Shares | shares |
|
42,989
|
|
42,989
|
|
42,989
|
|
42,989
|
|
Consumer & Business Products | TechStyle, Inc. (p.k.a. Just Fabulous, Inc.) | Warrant Investment | Preferred Series B |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[1] |
|
|
|
|
$ 1,101
|
|
|
|
Total investments at fair value |
|
|
|
|
|
$ 2,181
|
|
|
|
Acquisition Date |
[6] |
|
|
|
|
Jul. 16, 2013
|
|
Jul. 16, 2013
|
|
Shares | shares |
|
|
|
|
|
206,185
|
|
206,185
|
|
Consumer & Business Products | Gadget Guard, LLC | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 228
|
|
|
|
|
|
|
|
Total investments at fair value |
|
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Jun. 03, 2014
|
|
Jun. 03, 2014
|
|
|
|
|
|
Shares | shares |
|
1,662,441
|
|
1,662,441
|
|
|
|
|
|
Consumer & Business Services | Debt Investments |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 444,703
|
|
|
|
|
|
|
|
Total investments at fair value |
|
428,750
|
|
|
|
|
|
|
|
Consumer & Business Services | Equity |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
13,488
|
|
|
|
|
|
|
|
Total investments at fair value |
|
7,995
|
|
|
|
|
|
|
|
Consumer & Business Services | Warrant Investment |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
4,248
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 2,639
|
|
|
|
|
|
|
|
Consumer & Business Services | Jobandtalent USA, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2025-02
|
|
2025-02
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
9.75%
|
|
9.75%
|
|
|
|
|
|
Principal Amount |
[23],[24] |
$ 14,000
|
|
|
|
|
|
|
|
Investment cost |
[2],[23],[24] |
13,853
|
|
|
|
|
|
|
|
Total investments at fair value |
[23],[24] |
$ 13,904
|
|
|
|
|
|
|
|
Consumer & Business Services | Jobandtalent USA, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
3.00%
|
|
3.00%
|
|
|
|
|
|
Consumer & Business Services | Jobandtalent USA, Inc. | Senior Secured Debt | SOFR |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
8.86%
|
|
8.86%
|
|
|
|
|
|
Consumer & Business Services | Provi | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-12
|
|
2026-12
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
10.65%
|
|
10.65%
|
|
|
|
|
|
Principal Amount |
[25] |
$ 15,000
|
|
|
|
|
|
|
|
Investment cost |
[2],[25] |
14,739
|
|
|
|
|
|
|
|
Total investments at fair value |
[25] |
$ 14,739
|
|
|
|
|
|
|
|
Consumer & Business Services | Provi | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
2.95%
|
|
2.95%
|
|
|
|
|
|
Consumer & Business Services | Provi | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
4.40%
|
|
4.40%
|
|
|
|
|
|
Consumer & Business Services | Provi | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[25] |
$ 166
|
|
|
|
|
|
|
|
Total investments at fair value |
[25] |
$ 155
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Dec. 22, 2022
|
|
Dec. 22, 2022
|
|
|
|
|
|
Shares | shares |
[25] |
117,042
|
|
117,042
|
|
|
|
|
|
Consumer & Business Services | Veem, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2025-03
|
|
2025-03
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
7.25%
|
|
7.25%
|
|
|
|
|
|
Investment Interest Rate Paid in Kind |
[7] |
1.25%
|
|
1.25%
|
|
|
|
|
|
Principal Amount |
[11],[17] |
$ 5,043
|
|
|
|
|
|
|
|
Investment cost |
[2],[11],[17] |
5,000
|
|
|
|
|
|
|
|
Total investments at fair value |
[11],[17] |
$ 5,042
|
|
|
|
|
|
|
|
Consumer & Business Services | Veem, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
4.50%
|
|
4.50%
|
|
|
|
|
|
Consumer & Business Services | Veem, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
4.00%
|
|
4.00%
|
|
|
|
|
|
Consumer & Business Services | Veem, Inc. | Debt Investments |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Principal Amount |
|
$ 10,076
|
|
|
|
|
|
|
|
Investment cost |
[2] |
9,988
|
|
|
|
|
|
|
|
Total investments at fair value |
|
10,166
|
|
|
|
|
|
|
|
Consumer & Business Services | Veem, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
126
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 25
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Mar. 31, 2022
|
|
Mar. 31, 2022
|
|
|
|
|
|
Shares | shares |
|
98,428
|
|
98,428
|
|
|
|
|
|
Consumer & Business Services | Veem, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2025-03
|
|
2025-03
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
7.95%
|
|
7.95%
|
|
|
|
|
|
Investment Interest Rate Paid in Kind |
[7] |
1.50%
|
|
1.50%
|
|
|
|
|
|
Principal Amount |
[11] |
$ 5,033
|
|
|
|
|
|
|
|
Investment cost |
[2],[11] |
4,988
|
|
|
|
|
|
|
|
Total investments at fair value |
[11] |
$ 5,124
|
|
|
|
|
|
|
|
Consumer & Business Services | Veem, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
4.50%
|
|
4.50%
|
|
|
|
|
|
Consumer & Business Services | Veem, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
4.70%
|
|
4.70%
|
|
|
|
|
|
Consumer & Business Services | RVShare, LLC | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-12
|
|
2026-12
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
6.50%
|
|
6.50%
|
|
|
|
|
|
Investment Interest Rate Paid in Kind |
[7] |
4.00%
|
|
4.00%
|
|
|
|
|
|
Principal Amount |
[8],[11],[17],[25] |
$ 27,730
|
|
|
|
|
|
|
|
Investment cost |
[2],[8],[11],[17],[25] |
27,265
|
|
|
|
|
|
|
|
Total investments at fair value |
[8],[11],[17],[25] |
$ 27,256
|
|
|
|
|
|
|
|
Consumer & Business Services | RVShare, LLC | Senior Secured Debt | LIBOR |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
5.50%
|
|
5.50%
|
|
|
|
|
|
Consumer & Business Services | Snagajobcom Inc | Warrant Investment |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 860
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 118
|
|
|
|
|
|
|
|
Shares | shares |
|
3,611,537
|
|
3,611,537
|
|
|
|
|
|
Consumer & Business Services | Snagajobcom Inc | Warrant Investment | Preferred Series A |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 782
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 50
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Jun. 30, 2016
|
|
Jun. 30, 2016
|
|
|
|
|
|
Shares | shares |
|
1,800,000
|
|
1,800,000
|
|
|
|
|
|
Consumer & Business Services | Snagajobcom Inc | Warrant Investment | Preferred Series B |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 62
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 25
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Aug. 01, 2018
|
|
Aug. 01, 2018
|
|
|
|
|
|
Shares | shares |
|
1,211,537
|
|
1,211,537
|
|
|
|
|
|
Consumer & Business Services | Snagajobcom Inc | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 16
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 43
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Apr. 20, 2020
|
|
Apr. 20, 2020
|
|
|
|
|
|
Shares | shares |
|
600,000
|
|
600,000
|
|
|
|
|
|
Consumer & Business Services | RumbleON, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[9] |
$ 88
|
|
|
|
|
|
|
|
Total investments at fair value |
[9] |
$ 0
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Apr. 30, 2018
|
|
Apr. 30, 2018
|
|
|
|
|
|
Shares | shares |
[9] |
5,139
|
|
5,139
|
|
|
|
|
|
Consumer & Business Services | Lendio, Inc. | Warrant Investment | Preferred Series D |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 39
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 19
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Mar. 29, 2019
|
|
Mar. 29, 2019
|
|
|
|
|
|
Shares | shares |
|
127,032
|
|
127,032
|
|
|
|
|
|
Consumer & Business Services | Landing Holdings Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[25] |
$ 116
|
|
|
|
|
|
|
|
Total investments at fair value |
[25] |
$ 127
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Mar. 12, 2021
|
|
Mar. 12, 2021
|
|
|
|
|
|
Shares | shares |
[25] |
11,806
|
|
11,806
|
|
|
|
|
|
Consumer & Business Services | Lyft Inc | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[9] |
$ 5,263
|
|
|
|
|
|
|
|
Total investments at fair value |
[9] |
$ 1,110
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Dec. 26, 2018
|
|
Dec. 26, 2018
|
|
|
|
|
|
Shares | shares |
[9] |
100,738
|
|
100,738
|
|
|
|
|
|
Consumer & Business Services | Uber Technologies, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[9] |
$ 318
|
|
|
|
|
|
|
|
Total investments at fair value |
[9] |
$ 816
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Dec. 01, 2020
|
|
Dec. 01, 2020
|
|
|
|
|
|
Shares | shares |
[9] |
32,991
|
|
32,991
|
|
|
|
|
|
Consumer & Business Services | Nerdy Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[9] |
$ 1,000
|
|
|
|
|
|
|
|
Total investments at fair value |
[9] |
$ 225
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Sep. 17, 2021
|
|
Sep. 17, 2021
|
|
|
|
|
|
Shares | shares |
[9] |
100,000
|
|
100,000
|
|
|
|
|
|
Consumer & Business Services | DoorDash, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[9] |
$ 945
|
|
|
|
|
|
|
|
Total investments at fair value |
[9] |
$ 4,003
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Dec. 20, 2018
|
|
Dec. 20, 2018
|
|
|
|
|
|
Shares | shares |
[9] |
81,996
|
|
81,996
|
|
|
|
|
|
Consumer & Business Services | OfferUp, Inc. | Equity |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 2,295
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 513
|
|
|
|
|
|
|
|
Shares | shares |
|
394,790
|
|
394,790
|
|
|
|
|
|
Consumer & Business Services | OfferUp, Inc. | Equity | Preferred Series A |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 1,663
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 372
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Oct. 25, 2016
|
|
Oct. 25, 2016
|
|
|
|
|
|
Shares | shares |
|
286,080
|
|
286,080
|
|
|
|
|
|
Consumer & Business Services | OfferUp, Inc. | Equity | Preferred Series A-1 |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 632
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 141
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Oct. 25, 2016
|
|
Oct. 25, 2016
|
|
|
|
|
|
Shares | shares |
|
108,710
|
|
108,710
|
|
|
|
|
|
Consumer & Business Services | Oportun | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[9] |
$ 577
|
|
|
|
|
|
|
|
Total investments at fair value |
[9] |
$ 266
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Jun. 28, 2013
|
|
Jun. 28, 2013
|
|
|
|
|
|
Shares | shares |
[9] |
48,365
|
|
48,365
|
|
|
|
|
|
Consumer & Business Services | Reischling Press, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 39
|
|
|
|
|
|
|
|
Total investments at fair value |
|
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Jul. 31, 2020
|
|
Jul. 31, 2020
|
|
|
|
|
|
Shares | shares |
|
3,095
|
|
3,095
|
|
|
|
|
|
Consumer & Business Services | App Direct Incorporation | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-04
|
|
2026-04
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
8.75%
|
|
8.75%
|
|
|
|
|
|
Principal Amount |
[8],[18] |
$ 40,790
|
|
|
|
|
|
|
|
Investment cost |
[2],[8],[18] |
41,856
|
|
|
|
|
|
|
|
Total investments at fair value |
[8],[18] |
$ 42,426
|
|
|
|
|
|
|
|
Consumer & Business Services | App Direct Incorporation | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
8.29%
|
|
8.29%
|
|
|
|
|
|
Consumer & Business Services | App Direct Incorporation | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
5.50%
|
|
5.50%
|
|
|
|
|
|
Consumer & Business Services | Carwow LTD | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2024-12
|
|
2024-12
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
7.95%
|
|
7.95%
|
|
|
|
|
|
Investment Interest Rate Paid in Kind |
[7] |
1.45%
|
|
1.45%
|
|
|
|
|
|
Principal Amount | £ |
[11],[23],[24] |
|
|
£ 18,890
|
|
|
|
|
|
Investment cost |
[2],[11],[23],[24] |
$ 26,024
|
|
|
|
|
|
|
|
Total investments at fair value |
[11],[23],[24] |
$ 22,971
|
|
|
|
|
|
|
|
Consumer & Business Services | Carwow LTD | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
4.95%
|
|
4.95%
|
|
|
|
|
|
Consumer & Business Services | Carwow LTD | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
4.70%
|
|
4.70%
|
|
|
|
|
|
Consumer & Business Services | Carwow LTD | Equity | Preferred Series D-4 |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[23],[24] |
$ 1,151
|
|
|
|
|
|
|
|
Total investments at fair value |
[23],[24] |
$ 257
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Dec. 15, 2021
|
|
Dec. 15, 2021
|
|
|
|
|
|
Shares | shares |
[23],[24] |
199,742
|
|
199,742
|
|
|
|
|
|
Consumer & Business Services | Carwow LTD | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[23],[24] |
$ 164
|
|
|
|
|
|
|
|
Total investments at fair value |
[23],[24] |
$ 34
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Dec. 14, 2021
|
|
Dec. 14, 2021
|
|
|
|
|
|
Shares | shares |
[23],[24] |
174,163
|
|
174,163
|
|
|
|
|
|
Consumer & Business Services | Houzz, Inc. | Convertible Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2028-05
|
|
2028-05
|
|
|
|
|
|
Investment Interest Rate Paid in Kind |
[7] |
5.50%
|
|
5.50%
|
|
|
|
|
|
Principal Amount |
[11],[26] |
$ 21,853
|
|
|
|
|
|
|
|
Investment cost |
[2],[11],[26] |
21,853
|
|
|
|
|
|
|
|
Total investments at fair value |
[11],[26] |
20,356
|
|
|
|
|
|
|
|
Consumer & Business Services | Houzz, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
20
|
|
|
|
|
|
|
|
Total investments at fair value |
|
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Oct. 29, 2019
|
|
Oct. 29, 2019
|
|
|
|
|
|
Shares | shares |
|
529,661
|
|
529,661
|
|
|
|
|
|
Consumer & Business Services | Rhino Labs Incorporation | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2024-03
|
|
2024-03
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
8.75%
|
|
8.75%
|
|
|
|
|
|
Investment Interest Rate Paid in Kind |
[7] |
2.25%
|
|
2.25%
|
|
|
|
|
|
Principal Amount |
[11],[25] |
$ 16,500
|
|
|
|
|
|
|
|
Investment cost |
[2],[11],[25] |
16,328
|
|
|
|
|
|
|
|
Total investments at fair value |
[11],[25] |
$ 16,496
|
|
|
|
|
|
|
|
Consumer & Business Services | Rhino Labs Incorporation | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
5.50%
|
|
5.50%
|
|
|
|
|
|
Consumer & Business Services | Rhino Labs Incorporation | Equity | Preferred Series B-2 |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 1,000
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 805
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Jan. 24, 2022
|
|
Jan. 24, 2022
|
|
|
|
|
|
Shares | shares |
|
7,063
|
|
7,063
|
|
|
|
|
|
Consumer & Business Services | Rhino Labs Incorporation | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[25] |
$ 470
|
|
|
|
|
|
|
|
Total investments at fair value |
[25] |
$ 308
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Mar. 12, 2021
|
|
Mar. 12, 2021
|
|
|
|
|
|
Shares | shares |
[25] |
13,106
|
|
13,106
|
|
|
|
|
|
Consumer & Business Services | SeatGeek, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2023-06
|
|
2023-06
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
10.50%
|
|
10.50%
|
|
|
|
|
|
Investment Interest Rate Paid in Kind |
[7] |
0.50%
|
|
0.50%
|
|
|
|
|
|
Principal Amount |
[11],[17],[18],[19] |
$ 60,915
|
|
|
|
|
|
|
|
Investment cost |
[2],[11],[17],[18],[19] |
60,721
|
|
|
|
|
|
|
|
Total investments at fair value |
[11],[17],[18],[19] |
$ 60,721
|
|
|
|
|
|
|
|
Consumer & Business Services | SeatGeek, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
5.00%
|
|
5.00%
|
|
|
|
|
|
Consumer & Business Services | SeatGeek, Inc. | Debt Investments |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Principal Amount |
|
$ 85,986
|
|
|
|
|
|
|
|
Investment cost |
[2] |
85,633
|
|
|
|
|
|
|
|
Total investments at fair value |
|
86,544
|
|
|
|
|
|
|
|
Consumer & Business Services | SeatGeek, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[18],[19] |
842
|
|
|
|
|
|
|
|
Total investments at fair value |
[18],[19] |
$ 1,332
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Jun. 12, 2019
|
|
Jun. 12, 2019
|
|
|
|
|
|
Shares | shares |
[18],[19] |
1,379,761
|
|
1,379,761
|
|
|
|
|
|
Consumer & Business Services | SeatGeek, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-05
|
|
2026-05
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
10.50%
|
|
10.50%
|
|
|
|
|
|
Investment Interest Rate Paid in Kind |
[7] |
0.50%
|
|
0.50%
|
|
|
|
|
|
Principal Amount |
[11],[13],[19] |
$ 25,071
|
|
|
|
|
|
|
|
Investment cost |
[2],[11],[13],[19] |
24,912
|
|
|
|
|
|
|
|
Total investments at fair value |
[11],[13],[19] |
$ 25,823
|
|
|
|
|
|
|
|
Consumer & Business Services | SeatGeek, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
7.00%
|
|
7.00%
|
|
|
|
|
|
Consumer & Business Services | Skyword, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-11
|
|
2026-11
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
9.25%
|
|
9.25%
|
|
|
|
|
|
Investment Interest Rate Paid in Kind |
[7] |
1.75%
|
|
1.75%
|
|
|
|
|
|
Principal Amount |
[11],[17] |
$ 9,007
|
|
|
|
|
|
|
|
Investment cost |
[2],[11],[17] |
8,918
|
|
|
|
|
|
|
|
Total investments at fair value |
[11],[17] |
$ 8,870
|
|
|
|
|
|
|
|
Consumer & Business Services | Skyword, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
3.00%
|
|
3.00%
|
|
|
|
|
|
Consumer & Business Services | Skyword, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
2.75%
|
|
2.75%
|
|
|
|
|
|
Consumer & Business Services | Skyword, Inc. | Warrant Investment |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 140
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 43
|
|
|
|
|
|
|
|
Shares | shares |
|
2,051,587
|
|
2,051,587
|
|
|
|
|
|
Consumer & Business Services | Skyword, Inc. | Warrant Investment | Preferred Series B |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 83
|
|
|
|
|
|
|
|
Total investments at fair value |
|
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Aug. 23, 2019
|
|
Aug. 23, 2019
|
|
|
|
|
|
Shares | shares |
|
444,444
|
|
444,444
|
|
|
|
|
|
Consumer & Business Services | Skyword, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 57
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 43
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Nov. 14, 2022
|
|
Nov. 14, 2022
|
|
|
|
|
|
Shares | shares |
|
1,607,143
|
|
1,607,143
|
|
|
|
|
|
Consumer & Business Services | Tectura Corporation | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2024-07
|
|
2024-07
|
|
|
|
|
|
Investment Interest Rate Paid in Kind |
[7] |
5.00%
|
|
5.00%
|
|
|
|
|
|
Principal Amount |
[11],[27],[28] |
$ 10,680
|
|
|
|
|
|
|
|
Investment cost |
[2],[11],[27],[28] |
240
|
|
|
|
|
|
|
|
Total investments at fair value |
[11],[27],[28] |
0
|
|
|
|
|
|
|
|
Consumer & Business Services | Tectura Corporation | Debt Investments |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Principal Amount |
|
31,953
|
|
|
|
|
|
|
|
Investment cost |
[2] |
21,513
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 8,042
|
|
|
|
|
|
|
|
Consumer & Business Services | Tectura Corporation | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2024-07
|
|
2024-07
|
|
|
|
|
|
Principal Amount |
[11],[27],[28] |
$ 8,250
|
|
|
|
|
|
|
|
Investment Interest Rate Paid in Cash |
[7] |
8.25%
|
|
8.25%
|
|
|
|
|
|
Investment cost |
[2],[11],[27],[28] |
$ 8,250
|
|
|
|
|
|
|
|
Total investments at fair value |
[11],[27],[28] |
$ 8,042
|
|
|
|
|
|
|
|
Consumer & Business Services | Tectura Corporation | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2024-07
|
|
2024-07
|
|
|
|
|
|
Investment Interest Rate Paid in Kind |
[7] |
5.00%
|
|
5.00%
|
|
|
|
|
|
Principal Amount |
[11],[27],[28] |
$ 13,023
|
|
|
|
|
|
|
|
Investment cost |
[2],[11],[27],[28] |
13,023
|
|
|
|
|
|
|
|
Total investments at fair value |
[11],[27],[28] |
0
|
|
|
|
|
|
|
|
Consumer & Business Services | Tectura Corporation | Equity |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
900
|
|
|
|
|
|
|
|
Total investments at fair value |
|
|
|
|
|
|
|
|
|
Shares | shares |
|
415,994,863
|
|
415,994,863
|
|
|
|
|
|
Consumer & Business Services | Tectura Corporation | Equity | Preferred Series BB |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[27] |
$ 0
|
|
|
|
|
|
|
|
Total investments at fair value |
[27] |
$ 0
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Jun. 06, 2016
|
|
Jun. 06, 2016
|
|
|
|
|
|
Shares | shares |
[27] |
1,000,000
|
|
1,000,000
|
|
|
|
|
|
Consumer & Business Services | Tectura Corporation | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[27] |
$ 900
|
|
|
|
|
|
|
|
Total investments at fair value |
[27] |
$ 0
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
May 23, 2018
|
|
May 23, 2018
|
|
|
|
|
|
Shares | shares |
[27] |
414,994,863
|
|
414,994,863
|
|
|
|
|
|
Consumer & Business Services | Thumbtack, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-04
|
|
2026-04
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
8.20%
|
|
8.20%
|
|
|
|
|
|
Investment Interest Rate Paid in Kind |
[7] |
1.50%
|
|
1.50%
|
|
|
|
|
|
Principal Amount |
[8],[11],[18] |
$ 10,103
|
|
|
|
|
|
|
|
Investment cost |
[2],[8],[11],[18] |
10,050
|
|
|
|
|
|
|
|
Total investments at fair value |
[8],[11],[18] |
$ 10,167
|
|
|
|
|
|
|
|
Consumer & Business Services | Thumbtack, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
3.95%
|
|
3.95%
|
|
|
|
|
|
Consumer & Business Services | Thumbtack, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
4.95%
|
|
4.95%
|
|
|
|
|
|
Consumer & Business Services | Thumbtack, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[18] |
$ 844
|
|
|
|
|
|
|
|
Total investments at fair value |
[18] |
$ 280
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
May 01, 2018
|
|
May 01, 2018
|
|
|
|
|
|
Shares | shares |
[18] |
267,225
|
|
267,225
|
|
|
|
|
|
Consumer & Business Services | Worldremit Group Limited | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2025-02
|
|
2025-02
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
10.25%
|
|
10.25%
|
|
|
|
|
|
Principal Amount |
[10],[13],[18],[19],[23],[24] |
$ 94,500
|
|
|
|
|
|
|
|
Investment cost |
[2],[10],[13],[18],[19],[23],[24] |
94,418
|
|
|
|
|
|
|
|
Total investments at fair value |
[10],[13],[18],[19],[23],[24] |
$ 93,837
|
|
|
|
|
|
|
|
Consumer & Business Services | Worldremit Group Limited | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
3.00%
|
|
3.00%
|
|
|
|
|
|
Consumer & Business Services | Worldremit Group Limited | Senior Secured Debt | LIBOR |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
9.25%
|
|
9.25%
|
|
|
|
|
|
Consumer & Business Services | Worldremit Group Limited | Warrant Investment |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 155
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 194
|
|
|
|
|
|
|
|
Shares | shares |
|
79,083
|
|
79,083
|
|
|
|
|
|
Consumer & Business Services | Worldremit Group Limited | Warrant Investment | Preferred Series D |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[18],[19],[23],[24] |
$ 129
|
|
|
|
|
|
|
|
Total investments at fair value |
[18],[19],[23],[24] |
$ 192
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Feb. 11, 2021
|
|
Feb. 11, 2021
|
|
|
|
|
|
Shares | shares |
[18],[19],[23],[24] |
77,215
|
|
77,215
|
|
|
|
|
|
Consumer & Business Services | Worldremit Group Limited | Warrant Investment | Preferred Series E |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[19],[23],[24] |
$ 26
|
|
|
|
|
|
|
|
Total investments at fair value |
[19],[23],[24] |
$ 2
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Aug. 27, 2021
|
|
Aug. 27, 2021
|
|
|
|
|
|
Shares | shares |
[19],[23],[24] |
1,868
|
|
1,868
|
|
|
|
|
|
Consumer & Business Services | Udacity, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2024-09
|
|
2024-09
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
7.75%
|
|
7.75%
|
|
|
|
|
|
Investment Interest Rate Paid in Kind |
[7] |
2.00%
|
|
2.00%
|
|
|
|
|
|
Principal Amount |
[11],[18] |
$ 51,937
|
|
|
|
|
|
|
|
Investment cost |
[2],[11],[18] |
52,265
|
|
|
|
|
|
|
|
Total investments at fair value |
[11],[18] |
$ 52,976
|
|
|
|
|
|
|
|
Consumer & Business Services | Udacity, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
3.00%
|
|
3.00%
|
|
|
|
|
|
Consumer & Business Services | Udacity, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
4.50%
|
|
4.50%
|
|
|
|
|
|
Consumer & Business Services | Udacity, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[18] |
$ 218
|
|
|
|
|
|
|
|
Total investments at fair value |
[18] |
$ 4
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Sep. 25, 2020
|
|
Sep. 25, 2020
|
|
|
|
|
|
Shares | shares |
[18] |
486,359
|
|
486,359
|
|
|
|
|
|
Diversified Financial Services |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 68,569
|
|
|
|
$ 65,073
|
|
|
|
Diversified Financial Services | Debt Investments |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
36,567
|
[2] |
|
|
33,738
|
[1] |
|
|
Total investments at fair value |
|
33,700
|
|
|
|
32,465
|
|
|
|
Diversified Financial Services | Equity |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
28,444
|
[2] |
|
|
28,041
|
[1] |
|
|
Total investments at fair value |
|
$ 34,869
|
|
|
|
$ 32,608
|
|
|
|
Diversified Financial Services | Gibraltar Business Capital, LLC | Unsecured |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-09
|
|
2026-09
|
|
2026-09
|
|
2026-09
|
|
Principal Amount |
|
$ 15,000
|
[27] |
|
|
$ 15,000
|
[29] |
|
|
Investment Interest Rate Paid in Cash |
|
14.50%
|
[7] |
14.50%
|
[7] |
14.50%
|
[12] |
14.50%
|
[12] |
Investment cost |
|
$ 14,715
|
[2],[27] |
|
|
$ 14,662
|
[1],[29] |
|
|
Total investments at fair value |
|
12,802
|
[27] |
|
|
13,818
|
[29] |
|
|
Diversified Financial Services | Gibraltar Business Capital, LLC | Debt Investments |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Principal Amount |
|
25,000
|
|
|
|
25,000
|
|
|
|
Investment cost |
|
24,567
|
[2] |
|
|
24,485
|
[1] |
|
|
Total investments at fair value |
|
21,700
|
|
|
|
23,212
|
|
|
|
Diversified Financial Services | Gibraltar Business Capital, LLC | Equity |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
28,006
|
[2] |
|
|
28,006
|
[1] |
|
|
Total investments at fair value |
|
$ 15,244
|
|
|
|
$ 20,618
|
|
|
|
Shares | shares |
|
11,432,752
|
|
11,432,752
|
|
11,432,752
|
|
11,432,752
|
|
Diversified Financial Services | Gibraltar Business Capital, LLC | Equity | Preferred Series A |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[27] |
$ 26,122
|
|
|
|
|
|
|
|
Total investments at fair value |
[27] |
$ 14,137
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Mar. 01, 2018
|
|
Mar. 01, 2018
|
|
|
|
|
|
Shares | shares |
[27] |
10,602,752
|
|
10,602,752
|
|
|
|
|
|
Diversified Financial Services | Gibraltar Business Capital, LLC | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 1,884
|
[2],[27] |
|
|
$ 1,884
|
[1],[29] |
|
|
Total investments at fair value |
|
$ 1,107
|
[27] |
|
|
$ 1,225
|
[29] |
|
|
Acquisition Date |
|
Mar. 01, 2018
|
[9] |
Mar. 01, 2018
|
[9] |
Mar. 01, 2018
|
[6] |
Mar. 01, 2018
|
[6] |
Shares | shares |
|
830,000
|
[27] |
830,000
|
[27] |
830,000
|
[29] |
830,000
|
[29] |
Diversified Financial Services | Gibraltar Business Capital L L C One | Unsecured |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-09
|
|
2026-09
|
|
2026-09
|
|
2026-09
|
|
Principal Amount |
|
$ 10,000
|
[27] |
|
|
$ 10,000
|
[29] |
|
|
Investment Interest Rate Paid in Cash |
|
11.50%
|
[7] |
11.50%
|
[7] |
11.50%
|
[12] |
11.50%
|
[12] |
Investment cost |
|
$ 9,852
|
[2],[27] |
|
|
$ 9,823
|
[1],[29] |
|
|
Total investments at fair value |
|
$ 8,898
|
[27] |
|
|
9,394
|
[29] |
|
|
Diversified Financial Services | Gibraltar Business Capital L L C One | Equity | Preferred Series A |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[29] |
|
|
|
|
26,122
|
|
|
|
Total investments at fair value |
[29] |
|
|
|
|
$ 19,393
|
|
|
|
Acquisition Date |
[6] |
|
|
|
|
Mar. 01, 2018
|
|
Mar. 01, 2018
|
|
Shares | shares |
[29] |
|
|
|
|
10,602,752
|
|
10,602,752
|
|
Diversified Financial Services | Hercules Adviser LLC | Unsecured |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2025-06
|
|
2025-06
|
|
2023-05
|
|
2023-05
|
|
Principal Amount |
|
$ 12,000
|
[27] |
|
|
$ 8,850
|
[29] |
|
|
Investment Interest Rate Paid in Cash |
|
5.00%
|
[7] |
5.00%
|
[7] |
5.00%
|
[12] |
5.00%
|
[12] |
Investment cost |
|
$ 12,000
|
[2],[27] |
|
|
$ 8,850
|
[1],[29] |
|
|
Total investments at fair value |
|
12,000
|
[27] |
|
|
8,850
|
[29] |
|
|
Diversified Financial Services | Hercules Adviser LLC | Equity | Member Units |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
35
|
[2],[27] |
|
|
35
|
[1],[29] |
|
|
Total investments at fair value |
|
$ 19,153
|
[27] |
|
|
$ 11,990
|
[29] |
|
|
Acquisition Date |
|
Mar. 26, 2021
|
[9] |
Mar. 26, 2021
|
[9] |
Mar. 26, 2021
|
[6] |
Mar. 26, 2021
|
[6] |
Shares | shares |
|
1
|
[27] |
1
|
[27] |
1
|
[29] |
1
|
[29] |
Diversified Financial Services | Newfront Insurance Holdings, Inc. | Convertible Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
|
|
|
|
2022-08
|
|
2022-08
|
|
Investment Interest Rate Floor |
[12] |
|
|
|
|
0.19%
|
|
0.19%
|
|
Investment Interest Rate Paid in Kind |
[12] |
|
|
|
|
0.19%
|
|
0.19%
|
|
Principal Amount |
[30] |
|
|
|
|
$ 403
|
|
|
|
Investment cost |
[1],[30] |
|
|
|
|
403
|
|
|
|
Total investments at fair value |
[30] |
|
|
|
|
403
|
|
|
|
Diversified Financial Services | Newfront Insurance Holdings, Inc. | Equity | Preferred Series D-2 |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 403
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 472
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Sep. 30, 2021
|
|
Sep. 30, 2021
|
|
|
|
|
|
Shares | shares |
|
210,282
|
|
210,282
|
|
|
|
|
|
Drug Delivery |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 90
|
|
|
|
368
|
|
|
|
Drug Delivery | Equity |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
3,638
|
[2] |
|
|
3,638
|
[1] |
|
|
Total investments at fair value |
|
89
|
|
|
|
305
|
|
|
|
Drug Delivery | Warrant Investment |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
465
|
[2] |
|
|
465
|
[1] |
|
|
Total investments at fair value |
|
1
|
|
|
|
63
|
|
|
|
Drug Delivery | PDS Biotechnology Corporation | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[9] |
390
|
|
|
|
|
|
|
|
Total investments at fair value |
[9] |
$ 1
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Aug. 28, 2014
|
|
Aug. 28, 2014
|
|
|
|
|
|
Shares | shares |
[9] |
3,929
|
|
3,929
|
|
|
|
|
|
Drug Delivery | Aerami Therapeutics Holdings, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 74
|
[2] |
|
|
74
|
[1] |
|
|
Total investments at fair value |
|
|
|
|
|
$ 0
|
|
|
|
Acquisition Date |
|
Sep. 30, 2015
|
[9] |
Sep. 30, 2015
|
[9] |
Sep. 30, 2015
|
[6] |
Sep. 30, 2015
|
[6] |
Shares | shares |
|
110,882
|
|
110,882
|
|
110,882
|
|
110,882
|
|
Drug Delivery | PDS Biotechnology Corporation (p.k.a. Edge Therapeutics, Inc.) | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 309
|
[2],[9] |
|
|
$ 309
|
[1],[6] |
|
|
Total investments at fair value |
|
$ 33
|
[9] |
|
|
$ 20
|
[6] |
|
|
Acquisition Date |
|
Apr. 06, 2015
|
[9] |
Apr. 06, 2015
|
[9] |
Apr. 06, 2015
|
[6] |
Apr. 06, 2015
|
[6] |
Shares | shares |
|
2,498
|
[9] |
2,498
|
[9] |
2,498
|
[6] |
2,498
|
[6] |
Drug Delivery | PDS Biotechnology Corporation (p.k.a. Edge Therapeutics, Inc.) | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[6] |
|
|
|
|
$ 390
|
|
|
|
Total investments at fair value |
[6] |
|
|
|
|
$ 1
|
|
|
|
Acquisition Date |
[6] |
|
|
|
|
Aug. 28, 2014
|
|
Aug. 28, 2014
|
|
Shares | shares |
[6] |
|
|
|
|
3,929
|
|
3,929
|
|
Drug Delivery | BioQ Pharma Incorporated | Equity | Preferred Series D |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 500
|
[2] |
|
|
$ 500
|
[1] |
|
|
Total investments at fair value |
|
$ 33
|
|
|
|
$ 168
|
|
|
|
Acquisition Date |
|
Dec. 08, 2015
|
[9] |
Dec. 08, 2015
|
[9] |
Dec. 08, 2015
|
[6] |
Dec. 08, 2015
|
[6] |
Shares | shares |
|
165,000
|
|
165,000
|
|
165,000
|
|
165,000
|
|
Drug Delivery | BioQ Pharma Incorporated | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 1
|
[2] |
|
|
$ 1
|
[1] |
|
|
Total investments at fair value |
|
|
|
|
|
$ 62
|
|
|
|
Acquisition Date |
|
Oct. 27, 2014
|
[9] |
Oct. 27, 2014
|
[9] |
Oct. 27, 2014
|
[6] |
Oct. 27, 2014
|
[6] |
Shares | shares |
|
459,183
|
|
459,183
|
|
459,183
|
|
459,183
|
|
Drug Delivery | Aytu BioScience, Inc. (p.k.a. Neos Therapeutics, Inc.) | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 1,500
|
[2],[9] |
|
|
$ 1,500
|
[1],[6] |
|
|
Total investments at fair value |
|
$ 3
|
[9] |
|
|
$ 18
|
[6] |
|
|
Acquisition Date |
|
Mar. 28, 2014
|
[9] |
Mar. 28, 2014
|
[9] |
Mar. 28, 2014
|
[6] |
Mar. 28, 2014
|
[6] |
Shares | shares |
|
13,600
|
[9] |
13,600
|
[9] |
13,600
|
[6] |
13,600
|
[6] |
Drug Delivery | AcelRx Pharmaceuticals, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 1,329
|
[2],[9] |
|
|
$ 1,329
|
[1],[6] |
|
|
Total investments at fair value |
|
$ 20
|
[9] |
|
|
$ 99
|
[6] |
|
|
Acquisition Date |
|
Dec. 10, 2018
|
[9] |
Dec. 10, 2018
|
[9] |
Dec. 10, 2018
|
[6] |
Dec. 10, 2018
|
[6] |
Shares | shares |
|
8,836
|
[9] |
8,836
|
[9] |
176,730
|
[6] |
176,730
|
[6] |
Drug Discovery & Development |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 1,150,707
|
|
|
|
$ 967,383
|
|
|
|
Drug Discovery & Development | Investment Funds & Vehicles [Member] |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
3,118
|
|
|
|
|
|
|
|
Total investments at fair value |
|
3,518
|
|
|
|
|
|
|
|
Drug Discovery & Development | Debt Investments |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
1,107,352
|
[2] |
|
|
936,457
|
[1] |
|
|
Total investments at fair value |
|
1,101,430
|
|
|
|
935,964
|
|
|
|
Drug Discovery & Development | Equity |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
43,971
|
[2] |
|
|
33,401
|
[1] |
|
|
Total investments at fair value |
|
37,315
|
|
|
|
24,860
|
|
|
|
Drug Discovery & Development | Warrant Investment |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
7,466
|
[2] |
|
|
7,393
|
[1] |
|
|
Total investments at fair value |
|
8,444
|
|
|
|
4,745
|
|
|
|
Drug Discovery & Development | Forbion Growth Opportunities Fund I I C V | Investment Funds & Vehicles [Member] |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[8],[23],[24] |
419
|
|
|
|
|
|
|
|
Total investments at fair value |
[8],[23],[24] |
$ 438
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Jun. 23, 2022
|
|
Jun. 23, 2022
|
|
|
|
|
|
Drug Discovery & Development | Kineta, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[9] |
$ 110
|
|
|
|
|
|
|
|
Total investments at fair value |
[9] |
$ 0
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Dec. 20, 2019
|
|
Dec. 20, 2019
|
|
|
|
|
|
Shares | shares |
[9] |
2,202
|
|
2,202
|
|
|
|
|
|
Drug Discovery & Development | Akero Therapeutics, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2027-01
|
|
2027-01
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
7.65%
|
|
7.65%
|
|
|
|
|
|
Principal Amount |
[8],[17],[23] |
$ 5,000
|
|
|
|
|
|
|
|
Investment cost |
[2],[8],[17],[23] |
4,986
|
|
|
|
|
|
|
|
Total investments at fair value |
[8],[17],[23] |
$ 5,039
|
|
|
|
|
|
|
|
Drug Discovery & Development | Akero Therapeutics, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
5.85%
|
|
5.85%
|
|
|
|
|
|
Drug Discovery & Development | Akero Therapeutics, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
3.65%
|
|
3.65%
|
|
|
|
|
|
Drug Discovery & Development | Akero Therapeutics, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[9],[23] |
$ 1,000
|
|
|
|
|
|
|
|
Total investments at fair value |
[9],[23] |
$ 2,108
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Sep. 19, 2022
|
|
Sep. 19, 2022
|
|
|
|
|
|
Shares | shares |
[9],[23] |
38,461
|
|
38,461
|
|
|
|
|
|
Drug Discovery & Development | Akero Therapeutics, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[9],[23] |
$ 56
|
|
|
|
|
|
|
|
Total investments at fair value |
[9],[23] |
$ 674
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Jun. 15, 2022
|
|
Jun. 15, 2022
|
|
|
|
|
|
Shares | shares |
[9],[23] |
18,360
|
|
18,360
|
|
|
|
|
|
Drug Discovery & Development | Alladapt Immunotherapeutics Inc | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-09
|
|
2026-09
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
8.40%
|
|
8.40%
|
|
|
|
|
|
Principal Amount |
[8],[17] |
$ 15,000
|
|
|
|
|
|
|
|
Investment cost |
[2],[8],[17] |
14,920
|
|
|
|
|
|
|
|
Total investments at fair value |
[8],[17] |
$ 14,920
|
|
|
|
|
|
|
|
Drug Discovery & Development | Alladapt Immunotherapeutics Inc | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
10.60%
|
|
10.60%
|
|
|
|
|
|
Drug Discovery & Development | Alladapt Immunotherapeutics Inc | Senior Secured Debt | Cap rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
10.90%
|
|
10.90%
|
|
|
|
|
|
Drug Discovery & Development | Alladapt Immunotherapeutics Inc | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
3.65%
|
|
3.65%
|
|
|
|
|
|
Drug Discovery & Development | ATAI Life Sciences N.V. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-08
|
|
2026-08
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
8.55%
|
|
8.55%
|
|
|
|
|
|
Principal Amount |
[23],[24] |
$ 10,500
|
|
|
|
|
|
|
|
Investment cost |
[2],[23],[24] |
10,513
|
|
|
|
|
|
|
|
Total investments at fair value |
[23],[24] |
$ 10,513
|
|
|
|
|
|
|
|
Drug Discovery & Development | ATAI Life Sciences N.V. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
6.95%
|
|
6.95%
|
|
|
|
|
|
Drug Discovery & Development | ATAI Life Sciences N.V. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
4.55%
|
|
4.55%
|
|
|
|
|
|
Drug Discovery & Development | Provention Bio, Inc. [Member] | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2027-09
|
|
2027-09
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
8.20%
|
|
8.20%
|
|
|
|
|
|
Principal Amount |
[8] |
$ 25,000
|
|
|
|
|
|
|
|
Investment cost |
[2],[8] |
24,670
|
|
|
|
|
|
|
|
Total investments at fair value |
[8] |
$ 24,670
|
|
|
|
|
|
|
|
Drug Discovery & Development | Provention Bio, Inc. [Member] | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
6.60%
|
|
6.60%
|
|
|
|
|
|
Drug Discovery & Development | Provention Bio, Inc. [Member] | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
2.70%
|
|
2.70%
|
|
|
|
|
|
Drug Discovery & Development | Provention Bio, Inc. [Member] | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[9] |
$ 281
|
|
|
|
|
|
|
|
Total investments at fair value |
[9] |
$ 677
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Sep. 15, 2022
|
|
Sep. 15, 2022
|
|
|
|
|
|
Shares | shares |
[9] |
111,934
|
|
111,934
|
|
|
|
|
|
Drug Discovery & Development | Redshift Bioanalytics, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-01
|
|
2026-01
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
7.50%
|
|
7.50%
|
|
|
|
|
|
Principal Amount |
[25] |
$ 5,000
|
|
|
|
|
|
|
|
Investment cost |
[2],[25] |
4,957
|
|
|
|
|
|
|
|
Total investments at fair value |
[25] |
$ 4,946
|
|
|
|
|
|
|
|
Drug Discovery & Development | Redshift Bioanalytics, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
3.80%
|
|
3.80%
|
|
|
|
|
|
Drug Discovery & Development | Redshift Bioanalytics, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
4.25%
|
|
4.25%
|
|
|
|
|
|
Drug Discovery & Development | Redshift Bioanalytics, Inc. | Warrant Investment | Preferred Series E |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[25] |
$ 20
|
|
|
|
|
|
|
|
Total investments at fair value |
[25] |
$ 21
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Mar. 23, 2022
|
|
Mar. 23, 2022
|
|
|
|
|
|
Shares | shares |
[25] |
475,510
|
|
475,510
|
|
|
|
|
|
Drug Discovery & Development | Replimune Group, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2027-10
|
|
2027-10
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
7.25%
|
|
7.25%
|
|
|
|
|
|
Investment Interest Rate Paid in Kind |
[7] |
1.50%
|
|
1.50%
|
|
|
|
|
|
Principal Amount |
[8],[11],[23] |
$ 20,754
|
|
|
|
|
|
|
|
Investment cost |
[2],[8],[11],[23] |
20,656
|
|
|
|
|
|
|
|
Total investments at fair value |
[8],[11],[23] |
$ 20,656
|
|
|
|
|
|
|
|
Drug Discovery & Development | Replimune Group, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
4.95%
|
|
4.95%
|
|
|
|
|
|
Drug Discovery & Development | Replimune Group, Inc. | Senior Secured Debt | Cap rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
9.00%
|
|
9.00%
|
|
|
|
|
|
Drug Discovery & Development | Replimune Group, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
1.75%
|
|
1.75%
|
|
|
|
|
|
Drug Discovery & Development | Tarsus Pharmaceuticals, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2027-02
|
|
2027-02
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
8.45%
|
|
8.45%
|
|
|
|
|
|
Principal Amount |
[8],[17],[23] |
$ 8,250
|
|
|
|
|
|
|
|
Investment cost |
[2],[8],[17],[23] |
8,274
|
|
|
|
|
|
|
|
Total investments at fair value |
[8],[17],[23] |
$ 8,423
|
|
|
|
|
|
|
|
Drug Discovery & Development | Tarsus Pharmaceuticals, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
4.75%
|
|
4.75%
|
|
|
|
|
|
Drug Discovery & Development | Tarsus Pharmaceuticals, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
5.20%
|
|
5.20%
|
|
|
|
|
|
Drug Discovery & Development | Tarsus Pharmaceuticals, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[9],[23] |
$ 2,100
|
|
|
|
|
|
|
|
Total investments at fair value |
[9],[23] |
$ 2,280
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
May 05, 2022
|
|
May 05, 2022
|
|
|
|
|
|
Shares | shares |
[9],[23] |
155,555
|
|
155,555
|
|
|
|
|
|
Drug Discovery & Development | Iveric Bio, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2027-08
|
|
2027-08
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
8.75%
|
|
8.75%
|
|
|
|
|
|
Principal Amount |
[18],[23] |
$ 49,500
|
|
|
|
|
|
|
|
Investment cost |
[2],[18],[23] |
49,090
|
|
|
|
|
|
|
|
Total investments at fair value |
[18],[23] |
$ 49,090
|
|
|
|
|
|
|
|
Drug Discovery & Development | Iveric Bio, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
4.25%
|
|
4.25%
|
|
|
|
|
|
Drug Discovery & Development | Iveric Bio, Inc. | Senior Secured Debt | Cap rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
10.25%
|
|
10.25%
|
|
|
|
|
|
Drug Discovery & Development | Iveric Bio, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
4.00%
|
|
4.00%
|
|
|
|
|
|
Drug Discovery & Development | AmplifyBio, LLC | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2027-01
|
|
2027-01
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
9.50%
|
|
9.50%
|
|
|
|
|
|
Principal Amount |
[25] |
$ 24,000
|
|
|
|
|
|
|
|
Investment cost |
[2],[25] |
23,663
|
|
|
|
|
|
|
|
Total investments at fair value |
[25] |
$ 23,663
|
|
|
|
|
|
|
|
Drug Discovery & Development | AmplifyBio, LLC | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
5.85%
|
|
5.85%
|
|
|
|
|
|
Drug Discovery & Development | AmplifyBio, LLC | Senior Secured Debt | Cap rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
10.75%
|
|
10.75%
|
|
|
|
|
|
Drug Discovery & Development | AmplifyBio, LLC | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
2.50%
|
|
2.50%
|
|
|
|
|
|
Drug Discovery & Development | AmplifyBio, LLC | Warrant Investment | Class A Units |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[25] |
$ 238
|
|
|
|
|
|
|
|
Total investments at fair value |
[25] |
$ 256
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Dec. 27, 2022
|
|
Dec. 27, 2022
|
|
|
|
|
|
Shares | shares |
[25] |
69,239
|
|
69,239
|
|
|
|
|
|
Drug Discovery & Development | HilleVax, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2027-05
|
|
2027-05
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
4.55%
|
|
4.55%
|
|
|
|
|
|
Investment Interest Rate Paid in Kind |
[7] |
2.85%
|
|
2.85%
|
|
|
|
|
|
Principal Amount |
[8],[11],[25] |
$ 12,072
|
|
|
|
|
|
|
|
Investment cost |
[2],[8],[11],[25] |
12,043
|
|
|
|
|
|
|
|
Total investments at fair value |
[8],[11],[25] |
$ 11,333
|
|
|
|
|
|
|
|
Drug Discovery & Development | HilleVax, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
7.15%
|
|
7.15%
|
|
|
|
|
|
Drug Discovery & Development | HilleVax, Inc. | Senior Secured Debt | Cap rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
6.05%
|
|
6.05%
|
|
|
|
|
|
Drug Discovery & Development | HilleVax, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
1.05%
|
|
1.05%
|
|
|
|
|
|
Drug Discovery & Development | HilleVax, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[9] |
$ 4,000
|
|
|
|
|
|
|
|
Total investments at fair value |
[9] |
$ 3,937
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
May 03, 2022
|
|
May 03, 2022
|
|
|
|
|
|
Shares | shares |
[9] |
235,295
|
|
235,295
|
|
|
|
|
|
Drug Discovery & Development | Kura Oncology, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2027-11
|
|
2027-11
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
8.65%
|
|
8.65%
|
|
|
|
|
|
Principal Amount |
[8],[23],[25] |
$ 5,500
|
|
|
|
|
|
|
|
Investment cost |
[2],[8],[23],[25] |
5,448
|
|
|
|
|
|
|
|
Total investments at fair value |
[8],[23],[25] |
$ 5,448
|
|
|
|
|
|
|
|
Drug Discovery & Development | Kura Oncology, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
15.13%
|
|
15.13%
|
|
|
|
|
|
Drug Discovery & Development | Kura Oncology, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
2.40%
|
|
2.40%
|
|
|
|
|
|
Drug Discovery & Development | Kura Oncology, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[9],[23],[25] |
$ 88
|
|
|
|
|
|
|
|
Total investments at fair value |
[9],[23],[25] |
$ 59
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Nov. 02, 2022
|
|
Nov. 02, 2022
|
|
|
|
|
|
Shares | shares |
[9],[23],[25] |
14,342
|
|
14,342
|
|
|
|
|
|
Drug Discovery & Development | Madrigal Pharmaceutical, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-05
|
|
2026-05
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
7.45%
|
|
7.45%
|
|
|
|
|
|
Principal Amount |
[8],[23] |
$ 34,000
|
|
|
|
|
|
|
|
Investment cost |
[2],[8],[23] |
33,945
|
|
|
|
|
|
|
|
Total investments at fair value |
[8],[23] |
$ 33,987
|
|
|
|
|
|
|
|
Drug Discovery & Development | Madrigal Pharmaceutical, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
5.35%
|
|
5.35%
|
|
|
|
|
|
Drug Discovery & Development | Madrigal Pharmaceutical, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
3.95%
|
|
3.95%
|
|
|
|
|
|
Drug Discovery & Development | Madrigal Pharmaceutical, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[9],[23] |
$ 177
|
|
|
|
|
|
|
|
Total investments at fair value |
[9],[23] |
$ 1,977
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
May 09, 2022
|
|
May 09, 2022
|
|
|
|
|
|
Shares | shares |
[9],[23] |
10,131
|
|
10,131
|
|
|
|
|
|
Drug Discovery & Development | Forbion Growth Opportunities Fund I C V | Investment Funds & Vehicles [Member] |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[8],[23],[24] |
$ 2,699
|
|
|
|
|
|
|
|
Total investments at fair value |
[8],[23],[24] |
$ 3,080
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Nov. 16, 2020
|
|
Nov. 16, 2020
|
|
|
|
|
|
Drug Discovery & Development | Dynavax Technologies | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 550
|
[2],[9],[23] |
|
|
550
|
[1],[4],[6] |
|
|
Total investments at fair value |
|
$ 213
|
[9],[23] |
|
|
$ 281
|
[4],[6] |
|
|
Acquisition Date |
|
Jul. 22, 2015
|
[9] |
Jul. 22, 2015
|
[9] |
Jul. 22, 2015
|
[6] |
Jul. 22, 2015
|
[6] |
Shares | shares |
|
20,000
|
[9],[23] |
20,000
|
[9],[23] |
20,000
|
[4],[6] |
20,000
|
[4],[6] |
Drug Discovery & Development | Genocea Biosciences Inc | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[6] |
|
|
|
|
$ 2,000
|
|
|
|
Total investments at fair value |
[6] |
|
|
|
|
$ 32
|
|
|
|
Acquisition Date |
[6] |
|
|
|
|
Nov. 20, 2014
|
|
Nov. 20, 2014
|
|
Shares | shares |
[6] |
|
|
|
|
27,933
|
|
27,933
|
|
Drug Discovery & Development | Genocea Biosciences Inc | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[6] |
|
|
|
|
$ 165
|
|
|
|
Total investments at fair value |
[6] |
|
|
|
|
$ 1
|
|
|
|
Acquisition Date |
[6] |
|
|
|
|
Apr. 24, 2018
|
|
Apr. 24, 2018
|
|
Shares | shares |
[6] |
|
|
|
|
41,176
|
|
41,176
|
|
Drug Discovery & Development | NorthSea Therapeutics | Equity | Preferred Series C |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 2,000
|
[2],[23],[24] |
|
|
$ 2,000
|
[1],[4],[5] |
|
|
Total investments at fair value |
|
$ 1,476
|
[23],[24] |
|
|
$ 2,000
|
[4],[5] |
|
|
Acquisition Date |
|
Dec. 15, 2021
|
[9] |
Dec. 15, 2021
|
[9] |
Dec. 15, 2021
|
[6] |
Dec. 15, 2021
|
[6] |
Shares | shares |
|
983
|
[23],[24] |
983
|
[23],[24] |
983
|
[4],[5] |
983
|
[4],[5] |
Drug Discovery & Development | Sio Gene Therapies, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 1,269
|
[2],[9] |
|
|
$ 1,269
|
[1],[4],[6] |
|
|
Total investments at fair value |
|
$ 7
|
[9] |
|
|
$ 21
|
[4],[6] |
|
|
Acquisition Date |
|
Feb. 02, 2017
|
[9] |
Feb. 02, 2017
|
[9] |
Feb. 02, 2017
|
[6] |
Feb. 02, 2017
|
[6] |
Shares | shares |
|
16,228
|
[9] |
16,228
|
[9] |
16,228
|
[4],[6] |
16,228
|
[4],[6] |
Drug Discovery & Development | Valo Health L L C | Equity |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 4,000
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 3,075
|
|
|
|
|
|
|
|
Shares | shares |
|
680,410
|
|
680,410
|
|
|
|
|
|
Drug Discovery & Development | Valo Health L L C | Equity | Preferred Series B |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 3,000
|
[2] |
|
|
$ 3,000
|
[1] |
|
|
Total investments at fair value |
|
$ 2,063
|
|
|
|
$ 4,650
|
|
|
|
Acquisition Date |
|
Dec. 11, 2020
|
[9] |
Dec. 11, 2020
|
[9] |
Dec. 11, 2020
|
[6] |
Dec. 11, 2020
|
[6] |
Shares | shares |
|
510,308
|
|
510,308
|
|
510,308
|
|
510,308
|
|
Drug Discovery & Development | Valo Health L L C | Equity | Preferred Series C |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
$ 1,000
|
|
|
|
|
|
|
|
Total investments at fair value |
|
$ 1,012
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Oct. 31, 2022
|
|
Oct. 31, 2022
|
|
|
|
|
|
Shares | shares |
|
170,102
|
|
170,102
|
|
|
|
|
|
Drug Discovery & Development | Paratek Pharmaceuticals, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 2,744
|
[2],[9] |
|
|
$ 2,744
|
[1],[6] |
|
|
Total investments at fair value |
|
$ 143
|
[9] |
|
|
$ 343
|
[6] |
|
|
Acquisition Date |
|
Feb. 26, 2007
|
[9] |
Feb. 26, 2007
|
[9] |
Feb. 26, 2007
|
[6] |
Feb. 26, 2007
|
[6] |
Shares | shares |
|
76,362
|
[9] |
76,362
|
[9] |
76,362
|
[6] |
76,362
|
[6] |
Drug Discovery & Development | Paratek Pharmaceuticals, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 520
|
[2],[9] |
|
|
$ 546
|
[1],[6] |
|
|
Total investments at fair value |
|
$ 34
|
[9] |
|
|
$ 427
|
[6] |
|
|
Acquisition Date |
|
Aug. 01, 2018
|
[9] |
Aug. 01, 2018
|
[9] |
Jun. 27, 2017
|
[6] |
Jun. 27, 2017
|
[6] |
Shares | shares |
|
426,866
|
[9] |
426,866
|
[9] |
432,240
|
[6] |
432,240
|
[6] |
Drug Discovery & Development | Rocket Pharmaceuticals, Ltd. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 1,500
|
[2],[9] |
|
|
$ 1,500
|
[1],[6] |
|
|
Total investments at fair value |
|
$ 18
|
[9] |
|
|
$ 21
|
[6] |
|
|
Acquisition Date |
|
Aug. 22, 2007
|
[9] |
Aug. 22, 2007
|
[9] |
Aug. 22, 2007
|
[6] |
Aug. 22, 2007
|
[6] |
Shares | shares |
|
944
|
[9] |
944
|
[9] |
944
|
[6] |
944
|
[6] |
Drug Discovery & Development | Savara, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 203
|
[2],[9] |
|
|
$ 202
|
[1],[6] |
|
|
Total investments at fair value |
|
$ 17
|
[9] |
|
|
$ 14
|
[6] |
|
|
Acquisition Date |
|
Aug. 11, 2015
|
[9] |
Aug. 11, 2015
|
[9] |
Aug. 11, 2015
|
[6] |
Aug. 11, 2015
|
[6] |
Shares | shares |
|
11,119
|
[9] |
11,119
|
[9] |
11,119
|
[6] |
11,119
|
[6] |
Drug Discovery & Development | Tricida, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 863
|
[2],[9] |
|
|
$ 863
|
[1],[6] |
|
|
Total investments at fair value |
|
$ 11
|
[9] |
|
|
$ 658
|
[6] |
|
|
Acquisition Date |
|
Feb. 28, 2018
|
[9] |
Feb. 28, 2018
|
[9] |
Feb. 28, 2018
|
[6] |
Feb. 28, 2018
|
[6] |
Shares | shares |
|
68,816
|
[9] |
68,816
|
[9] |
68,816
|
[6] |
68,816
|
[6] |
Drug Discovery & Development | Tricida, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 280
|
[2],[9] |
|
|
$ 280
|
[1],[6] |
|
|
Total investments at fair value |
|
$ 1
|
[9] |
|
|
$ 20
|
[6] |
|
|
Acquisition Date |
|
Mar. 27, 2019
|
[9] |
Mar. 27, 2019
|
[9] |
Mar. 27, 2019
|
[6] |
Mar. 27, 2019
|
[6] |
Shares | shares |
|
31,352
|
[9] |
31,352
|
[9] |
31,352
|
[6] |
31,352
|
[6] |
Drug Discovery & Development | Concert Pharmaceuticals, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 1,367
|
[2],[9],[23] |
|
|
$ 1,367
|
[1],[4],[6] |
|
|
Total investments at fair value |
|
$ 413
|
[9],[23] |
|
|
$ 223
|
[4],[6] |
|
|
Acquisition Date |
|
Feb. 13, 2019
|
[9] |
Feb. 13, 2019
|
[9] |
Feb. 13, 2019
|
[6] |
Feb. 13, 2019
|
[6] |
Shares | shares |
|
70,796
|
[9],[23] |
70,796
|
[9],[23] |
70,796
|
[4],[6] |
70,796
|
[4],[6] |
Drug Discovery & Development | Concert Pharmaceuticals, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[4],[6] |
|
|
|
|
$ 178
|
|
|
|
Total investments at fair value |
[4],[6] |
|
|
|
|
$ 3
|
|
|
|
Acquisition Date |
[6] |
|
|
|
|
Jun. 08, 2017
|
|
Jun. 08, 2017
|
|
Shares | shares |
[4],[6] |
|
|
|
|
61,273
|
|
61,273
|
|
Drug Discovery & Development | Gritstone Bio, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2027-07
|
|
2027-07
|
|
|
|
|
|
Investment Interest Rate Floor |
[7] |
7.15%
|
|
7.15%
|
|
|
|
|
|
Investment Interest Rate Paid in Kind |
[7] |
2.00%
|
|
2.00%
|
|
|
|
|
|
Principal Amount |
[8],[11] |
$ 15,113
|
|
|
|
|
|
|
|
Investment cost |
[2],[8],[11] |
15,109
|
|
|
|
|
|
|
|
Total investments at fair value |
[8],[11] |
$ 15,109
|
|
|
|
|
|
|
|
Drug Discovery & Development | Gritstone Bio, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
5.75%
|
|
5.75%
|
|
|
|
|
|
Drug Discovery & Development | Gritstone Bio, Inc. | Senior Secured Debt | Cap rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
8.65%
|
|
8.65%
|
|
|
|
|
|
Drug Discovery & Development | Gritstone Bio, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[7] |
3.15%
|
|
3.15%
|
|
|
|
|
|
Drug Discovery & Development | Gritstone Bio, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[9] |
$ 1,000
|
|
|
|
|
|
|
|
Total investments at fair value |
[9] |
$ 1,527
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
Oct. 26, 2022
|
|
Oct. 26, 2022
|
|
|
|
|
|
Shares | shares |
[9] |
442,477
|
|
442,477
|
|
|
|
|
|
Drug Discovery & Development | Dare Biosciences, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 1,000
|
[2],[9] |
|
|
$ 1,000
|
[1],[6] |
|
|
Total investments at fair value |
|
$ 11
|
[9] |
|
|
$ 27
|
[6] |
|
|
Acquisition Date |
|
Jan. 08, 2015
|
[9] |
Jan. 08, 2015
|
[9] |
Jan. 08, 2015
|
[6] |
Jan. 08, 2015
|
[6] |
Shares | shares |
|
13,550
|
[9] |
13,550
|
[9] |
13,550
|
[6] |
13,550
|
[6] |
Drug Discovery & Development | Applied Molecular Transport | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 42
|
[2],[9],[23] |
|
|
$ 42
|
[1],[4],[6] |
|
|
Total investments at fair value |
|
$ 0
|
[9],[23] |
|
|
$ 14
|
[4],[6] |
|
|
Acquisition Date |
|
Apr. 06, 2021
|
[9] |
Apr. 06, 2021
|
[9] |
Apr. 06, 2021
|
[6] |
Apr. 06, 2021
|
[6] |
Shares | shares |
|
1,000
|
[9],[23] |
1,000
|
[9],[23] |
1,000
|
[4],[6] |
1,000
|
[4],[6] |
Drug Discovery & Development | Avalo Therapeutics Inc P K Cerecor Inc | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 1,000
|
[2],[9] |
|
|
$ 1,000
|
[1],[6] |
|
|
Total investments at fair value |
|
$ 50
|
[9] |
|
|
$ 202
|
[6] |
|
|
Acquisition Date |
|
Aug. 19, 2014
|
[9] |
Aug. 19, 2014
|
[9] |
Aug. 19, 2014
|
[6] |
Aug. 19, 2014
|
[6] |
Shares | shares |
|
9,924
|
[9] |
9,924
|
[9] |
119,087
|
[6] |
119,087
|
[6] |
Drug Discovery & Development | Albireo Pharma, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
|
|
|
|
2024-07
|
|
2024-07
|
|
Investment Interest Rate Floor |
[12] |
|
|
|
|
9.15%
|
|
9.15%
|
|
Principal Amount |
[4],[15] |
|
|
|
|
$ 10,000
|
|
|
|
Investment cost |
[1],[4],[15] |
|
|
|
|
10,229
|
|
|
|
Total investments at fair value |
[4],[15] |
|
|
|
|
$ 10,268
|
|
|
|
Drug Discovery & Development | Albireo Pharma, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[12] |
|
|
|
|
6.95%
|
|
6.95%
|
|
Drug Discovery & Development | Albireo Pharma, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[12] |
|
|
|
|
5.90%
|
|
5.90%
|
|
Drug Discovery & Development | Albireo Pharma, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 1,000
|
[2],[9],[23] |
|
|
$ 1,000
|
[1],[4],[6] |
|
|
Total investments at fair value |
|
$ 540
|
[9],[23] |
|
|
$ 582
|
[4],[6] |
|
|
Acquisition Date |
|
Sep. 14, 2020
|
[9] |
Sep. 14, 2020
|
[9] |
Sep. 14, 2020
|
[6] |
Sep. 14, 2020
|
[6] |
Shares | shares |
|
25,000
|
[9],[23] |
25,000
|
[9],[23] |
25,000
|
[4],[6] |
25,000
|
[4],[6] |
Drug Discovery & Development | Albireo Pharma, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 61
|
[2],[9],[23] |
|
|
$ 61
|
[1],[4],[6] |
|
|
Total investments at fair value |
|
$ 31
|
[9],[23] |
|
|
$ 42
|
[4],[6] |
|
|
Acquisition Date |
|
Jun. 08, 2020
|
[9] |
Jun. 08, 2020
|
[9] |
Jun. 08, 2020
|
[6] |
Jun. 08, 2020
|
[6] |
Shares | shares |
|
5,311
|
[9],[23] |
5,311
|
[9],[23] |
5,311
|
[4],[6] |
5,311
|
[4],[6] |
Drug Discovery & Development | Aldeyra Therapeutics, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2024-10
|
|
2024-10
|
|
2023-10
|
|
2023-10
|
|
Investment Interest Rate Floor |
|
8.60%
|
[7] |
8.60%
|
[7] |
8.60%
|
[12] |
8.60%
|
[12] |
Principal Amount |
|
$ 15,000
|
[13] |
|
|
$ 15,000
|
|
|
|
Investment cost |
|
15,879
|
[2],[13] |
|
|
15,639
|
[1] |
|
|
Total investments at fair value |
|
$ 15,974
|
[13] |
|
|
$ 15,653
|
|
|
|
Drug Discovery & Development | Aldeyra Therapeutics, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
|
8.90%
|
[7] |
8.90%
|
[7] |
6.95%
|
[12] |
6.95%
|
[12] |
Drug Discovery & Development | Aldeyra Therapeutics, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
|
3.10%
|
[7] |
3.10%
|
[7] |
3.10%
|
[12] |
3.10%
|
[12] |
Drug Discovery & Development | Applied Genetic Technologies Corporation | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
|
|
|
|
2024-04
|
|
2024-04
|
|
Investment Interest Rate Floor |
[12] |
|
|
|
|
9.75%
|
|
9.75%
|
|
Principal Amount |
|
|
|
|
|
$ 20,000
|
|
|
|
Investment cost |
[1] |
|
|
|
|
20,416
|
|
|
|
Total investments at fair value |
|
|
|
|
|
$ 20,339
|
|
|
|
Drug Discovery & Development | Applied Genetic Technologies Corporation | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[12] |
|
|
|
|
6.95%
|
|
6.95%
|
|
Drug Discovery & Development | Applied Genetic Technologies Corporation | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[12] |
|
|
|
|
6.50%
|
|
6.50%
|
|
Drug Discovery & Development | Aveo Pharmaceuticals, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2024-09
|
|
2024-09
|
|
2024-09
|
|
2024-09
|
|
Investment Interest Rate Floor |
|
9.65%
|
[7] |
9.65%
|
[7] |
9.65%
|
[12] |
9.65%
|
[12] |
Principal Amount |
|
$ 40,000
|
[13],[25] |
|
|
$ 40,000
|
[15],[31] |
|
|
Investment cost |
|
41,644
|
[2],[13],[25] |
|
|
40,842
|
[1],[15],[31] |
|
|
Total investments at fair value |
|
$ 43,183
|
[13],[25] |
|
|
$ 40,776
|
[15],[31] |
|
|
Drug Discovery & Development | Aveo Pharmaceuticals, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
|
6.95%
|
[7] |
6.95%
|
[7] |
6.95%
|
[12] |
6.95%
|
[12] |
Drug Discovery & Development | Aveo Pharmaceuticals, Inc. | Senior Secured Debt | Cap rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
15.00%
|
|
15.00%
|
|
|
|
|
|
Drug Discovery & Development | Aveo Pharmaceuticals, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
|
6.40%
|
[7] |
6.40%
|
[7] |
6.40%
|
[12] |
6.40%
|
[12] |
Drug Discovery & Development | Aveo Pharmaceuticals, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 1,715
|
[2],[9] |
|
|
$ 1,715
|
[1],[6] |
|
|
Total investments at fair value |
|
$ 2,843
|
[9] |
|
|
$ 892
|
[6] |
|
|
Acquisition Date |
|
Jul. 31, 2011
|
[9] |
Jul. 31, 2011
|
[9] |
Jul. 31, 2011
|
[6] |
Jul. 31, 2011
|
[6] |
Shares | shares |
|
190,179
|
[9] |
190,179
|
[9] |
190,179
|
[6] |
190,179
|
[6] |
Drug Discovery & Development | Acacia Pharma Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 304
|
[2],[23],[24] |
|
|
$ 305
|
[1],[4],[5],[6] |
|
|
Total investments at fair value |
|
$ 0
|
[23],[24] |
|
|
$ 6
|
[4],[5],[6] |
|
|
Acquisition Date |
|
Jun. 29, 2018
|
[9] |
Jun. 29, 2018
|
[9] |
Jun. 29, 2018
|
[6] |
Jun. 29, 2018
|
[6] |
Shares | shares |
|
201,330
|
[23],[24] |
201,330
|
[23],[24] |
201,330
|
[4],[5],[6] |
201,330
|
[4],[5],[6] |
Drug Discovery & Development | ADMA Biologics, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 166
|
[2],[9] |
|
|
$ 295
|
[1],[6] |
|
|
Total investments at fair value |
|
$ 10
|
[9] |
|
|
$ 1
|
[6] |
|
|
Acquisition Date |
|
Feb. 24, 2014
|
[9] |
Feb. 24, 2014
|
[9] |
Dec. 21, 2012
|
[6] |
Dec. 21, 2012
|
[6] |
Shares | shares |
|
58,000
|
[9] |
58,000
|
[9] |
89,750
|
[6] |
89,750
|
[6] |
Drug Discovery & Development | Axsome Therapeutics, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-10
|
|
2026-10
|
|
2026-10
|
|
2026-10
|
|
Investment Interest Rate Floor |
|
8.95%
|
[7] |
8.95%
|
[7] |
8.95%
|
[12] |
8.95%
|
[12] |
Principal Amount |
|
$ 81,725
|
[8],[13],[18],[19],[23] |
|
|
$ 50,000
|
[4],[32] |
|
|
Investment cost |
|
81,631
|
[2],[8],[13],[18],[19],[23] |
|
|
49,542
|
[1],[4],[32] |
|
|
Total investments at fair value |
|
$ 78,074
|
[8],[13],[18],[19],[23] |
|
|
$ 48,859
|
[4],[32] |
|
|
Drug Discovery & Development | Axsome Therapeutics, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
|
5.31%
|
[7] |
5.31%
|
[7] |
5.82%
|
[12] |
5.82%
|
[12] |
Drug Discovery & Development | Axsome Therapeutics, Inc. | Senior Secured Debt | Cap rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
10.70%
|
|
10.70%
|
|
|
|
|
|
Drug Discovery & Development | Axsome Therapeutics, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
|
5.70%
|
[7] |
5.70%
|
[7] |
5.70%
|
[12] |
5.70%
|
[12] |
Drug Discovery & Development | Axsome Therapeutics, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[9],[19],[23] |
$ 4,165
|
|
|
|
|
|
|
|
Total investments at fair value |
[9],[19],[23] |
$ 9,797
|
|
|
|
|
|
|
|
Acquisition Date |
[9] |
May 09, 2022
|
|
May 09, 2022
|
|
|
|
|
|
Shares | shares |
[9],[19],[23] |
127,021
|
|
127,021
|
|
|
|
|
|
Drug Discovery & Development | Axsome Therapeutics, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 880
|
[2],[9],[18],[19],[23] |
|
|
$ 681
|
[1],[4],[6] |
|
|
Total investments at fair value |
|
$ 1,590
|
[9],[18],[19],[23] |
|
|
$ 142
|
[4],[6] |
|
|
Acquisition Date |
|
Sep. 25, 2020
|
[9] |
Sep. 25, 2020
|
[9] |
Sep. 25, 2020
|
[6] |
Sep. 25, 2020
|
[6] |
Shares | shares |
|
40,396
|
[9],[18],[19],[23] |
40,396
|
[9],[18],[19],[23] |
15,541
|
[4],[6] |
15,541
|
[4],[6] |
Drug Discovery & Development | Brickell Biotech, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 119
|
[2],[9] |
|
|
$ 119
|
[1],[6] |
|
|
Total investments at fair value |
|
$ 0
|
[9] |
|
|
$ 0
|
[6] |
|
|
Acquisition Date |
|
Feb. 18, 2016
|
[9] |
Feb. 18, 2016
|
[9] |
Feb. 18, 2016
|
[6] |
Feb. 18, 2016
|
[6] |
Shares | shares |
|
200
|
[9] |
200
|
[9] |
9,005
|
[6] |
9,005
|
[6] |
Drug Discovery & Development | Bicycle Therapeutics PLC | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2025-07
|
|
2025-07
|
|
2024-10
|
|
2024-10
|
|
Investment Interest Rate Floor |
|
8.05%
|
[7] |
8.05%
|
[7] |
8.85%
|
[12] |
8.85%
|
[12] |
Principal Amount |
|
$ 11,500
|
[13],[18],[23],[24] |
|
|
$ 24,000
|
[3],[4],[5],[15],[32] |
|
|
Investment cost |
|
11,757
|
[2],[13],[18],[23],[24] |
|
|
24,271
|
[1],[3],[4],[5],[15],[32] |
|
|
Total investments at fair value |
|
$ 11,435
|
[13],[18],[23],[24] |
|
|
$ 24,454
|
[3],[4],[5],[15],[32] |
|
|
Drug Discovery & Development | Bicycle Therapeutics PLC | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
|
5.00%
|
[7] |
5.00%
|
[7] |
5.00%
|
[12] |
5.00%
|
[12] |
Drug Discovery & Development | Bicycle Therapeutics PLC | Senior Secured Debt | Cap rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
9.05%
|
|
9.05%
|
|
|
|
|
|
Drug Discovery & Development | Bicycle Therapeutics PLC | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
|
4.55%
|
[7] |
4.55%
|
[7] |
5.60%
|
[12] |
5.60%
|
[12] |
Drug Discovery & Development | Bicycle Therapeutics PLC | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 1,871
|
[2],[9],[23],[24] |
|
|
$ 1,871
|
[1],[4],[5],[6] |
|
|
Total investments at fair value |
|
$ 2,904
|
[9],[23],[24] |
|
|
$ 5,971
|
[4],[5],[6] |
|
|
Acquisition Date |
|
Oct. 05, 2020
|
[9] |
Oct. 05, 2020
|
[9] |
Oct. 05, 2020
|
[6] |
Oct. 05, 2020
|
[6] |
Shares | shares |
|
98,100
|
[9],[23],[24] |
98,100
|
[9],[23],[24] |
98,100
|
[4],[5],[6] |
98,100
|
[4],[5],[6] |
Drug Discovery & Development | BiomX, INC | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2025-09
|
|
2025-09
|
|
2025-09
|
|
2025-09
|
|
Investment Interest Rate Floor |
|
8.95%
|
[7] |
8.95%
|
[7] |
8.95%
|
[12] |
8.95%
|
[12] |
Principal Amount |
|
$ 9,000
|
[13],[23],[24] |
|
|
$ 9,000
|
[4],[5],[15] |
|
|
Investment cost |
|
9,174
|
[2],[13],[23],[24] |
|
|
8,980
|
[1],[4],[5],[15] |
|
|
Total investments at fair value |
|
$ 9,052
|
[13],[23],[24] |
|
|
$ 8,980
|
[4],[5],[15] |
|
|
Drug Discovery & Development | BiomX, INC | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
|
6.55%
|
[7] |
6.55%
|
[7] |
6.55%
|
[12] |
6.55%
|
[12] |
Drug Discovery & Development | BiomX, INC | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
|
5.70%
|
[7] |
5.70%
|
[7] |
5.70%
|
[12] |
5.70%
|
[12] |
Drug Discovery & Development | BridgeBio Pharma, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-11
|
|
2026-11
|
|
2026-11
|
|
2026-11
|
|
Principal Amount |
|
$ 37,312
|
[11],[17],[18] |
|
|
$ 38,000
|
|
|
|
Investment Interest Rate Paid in Cash |
|
9.00%
|
[7] |
9.00%
|
[7] |
9.00%
|
[12] |
9.00%
|
[12] |
Investment cost |
|
$ 37,039
|
[2],[11],[17],[18] |
|
|
$ 37,462
|
[1] |
|
|
Total investments at fair value |
|
$ 33,344
|
[11],[17],[18] |
|
|
$ 37,462
|
|
|
|
Drug Discovery & Development | BridgeBio Pharma, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
|
2.00%
|
[7] |
2.00%
|
[7] |
2.00%
|
[12] |
2.00%
|
[12] |
Drug Discovery & Development | BridgeBio Pharma, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 2,255
|
[2],[9] |
|
|
$ 2,255
|
[1],[6] |
|
|
Total investments at fair value |
|
$ 1,763
|
[9] |
|
|
$ 3,859
|
[6] |
|
|
Acquisition Date |
|
Jun. 21, 2018
|
[9] |
Jun. 21, 2018
|
[9] |
Jun. 21, 2018
|
[6] |
Jun. 21, 2018
|
[6] |
Shares | shares |
|
231,329
|
[9] |
231,329
|
[9] |
231,329
|
[6] |
231,329
|
[6] |
Drug Discovery & Development | Cellarity, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-06
|
|
2026-06
|
|
2026-06
|
|
2026-06
|
|
Investment Interest Rate Floor |
|
8.95%
|
[7] |
8.95%
|
[7] |
8.95%
|
[12] |
8.95%
|
[12] |
Principal Amount |
|
$ 30,000
|
[17],[25] |
|
|
$ 30,000
|
[31] |
|
|
Investment cost |
|
29,841
|
[2],[17],[25] |
|
|
29,422
|
[1],[31] |
|
|
Total investments at fair value |
|
$ 30,097
|
[17],[25] |
|
|
$ 29,422
|
[31] |
|
|
Drug Discovery & Development | Cellarity, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
|
3.75%
|
[7] |
3.75%
|
[7] |
3.75%
|
[12] |
3.75%
|
[12] |
Drug Discovery & Development | Cellarity, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
|
5.70%
|
[7] |
5.70%
|
[7] |
5.70%
|
[12] |
5.70%
|
[12] |
Drug Discovery & Development | Cellarity, Inc. | Warrant Investment | Preferred Series B |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 287
|
[2],[25] |
|
|
$ 287
|
[1],[31] |
|
|
Total investments at fair value |
|
$ 318
|
[25] |
|
|
$ 287
|
[31] |
|
|
Acquisition Date |
|
Dec. 08, 2021
|
[9] |
Dec. 08, 2021
|
[9] |
Dec. 08, 2021
|
[6] |
Dec. 08, 2021
|
[6] |
Shares | shares |
|
100,000
|
[25] |
100,000
|
[25] |
100,000
|
[31] |
100,000
|
[31] |
Drug Discovery & Development | Center for Breakthrough Medicines Holdings, LLC [Member] | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
|
|
|
|
2023-05
|
|
2023-05
|
|
Investment Interest Rate Floor |
[12] |
|
|
|
|
8.75%
|
|
8.75%
|
|
Principal Amount |
|
|
|
|
|
$ 5,000
|
|
|
|
Investment cost |
[1] |
|
|
|
|
5,005
|
|
|
|
Total investments at fair value |
|
|
|
|
|
$ 5,005
|
|
|
|
Drug Discovery & Development | Center for Breakthrough Medicines Holdings, LLC [Member] | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
[12] |
|
|
|
|
7.50%
|
|
7.50%
|
|
Drug Discovery & Development | Center for Breakthrough Medicines Holdings, LLC [Member] | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
[12] |
|
|
|
|
5.50%
|
|
5.50%
|
|
Drug Discovery & Development | Century Therapeutics, Inc. | Senior Secured Debt |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2024-04
|
|
2024-04
|
|
2024-04
|
|
2024-04
|
|
Investment Interest Rate Floor |
|
9.55%
|
[7] |
9.55%
|
[7] |
9.55%
|
[12] |
9.55%
|
[12] |
Principal Amount |
|
$ 10,000
|
[13] |
|
|
$ 10,000
|
[15] |
|
|
Investment cost |
|
10,235
|
[2],[13] |
|
|
10,075
|
[1],[15] |
|
|
Total investments at fair value |
|
$ 10,292
|
[13] |
|
|
$ 10,361
|
[15] |
|
|
Drug Discovery & Development | Century Therapeutics, Inc. | Senior Secured Debt | Exit Fee Interest Income |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Interest Rate and Floor |
|
3.95%
|
[7] |
3.95%
|
[7] |
3.95%
|
[12] |
3.95%
|
[12] |
Drug Discovery & Development | Century Therapeutics, Inc. | Senior Secured Debt | Prime Rate |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment Basis Spread Variable Rate |
|
6.30%
|
[7] |
6.30%
|
[7] |
6.30%
|
[12] |
6.30%
|
[12] |
Drug Discovery & Development | Century Therapeutics, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 37
|
[2],[9] |
|
|
$ 37
|
[1],[6] |
|
|
Total investments at fair value |
|
$ 3
|
[9] |
|
|
$ 64
|
[6] |
|
|
Acquisition Date |
|
Sep. 14, 2020
|
[9] |
Sep. 14, 2020
|
[9] |
Sep. 14, 2020
|
[6] |
Sep. 14, 2020
|
[6] |
Shares | shares |
|
16,112
|
[9] |
16,112
|
[9] |
16,112
|
[6] |
16,112
|
[6] |
Drug Discovery & Development | Chemocentryx Inc One | Senior Secured Debt |
|
|
|